SNDX250117C10000
- 2.90
- 0.000.00%
Syndax Pharmaceuticals Newsroom
Sector Update: Health Care Stocks Flat to Lower Premarket Thursday
Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes
Express News | Incyte Corp - Niktimvo Expected to Be Available in U.S. in Early February
Express News | Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (Axatilimab-Csfr) 9 Mg and 22 Mg Vial Sizes
Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) Five Years Ago Would Have Delivered You a 53% Gain
Scotiabank Maintains Syndax Pharmaceuticals(SNDX.US) With Hold Rating, Cuts Target Price to $16
Syndax Pharmaceuticals Is Maintained at Sector Perform by Scotiabank
Syndax Pharmaceuticals Analyst Ratings
Express News | Syndax Pharmaceuticals Inc : Scotiabank Cuts Target Price to $16 From $18
Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
Jefferies Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $43
BofA Securities Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $25
Express News | Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Restructures Leadership Team
Express News | Syndax Pharmaceuticals Inc - Eliminates Chief Medical Officer Position
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $33
Barclays Gives a Buy Rating to Syndax Pharmaceuticals (SNDX)
Trending Stocks Today | Micron Technology Falls 14.29% Post-Market
J.P. Morgan Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Raises Target Price to $39